Mukhopadhyay Mukhopadhyay S S Undermining Glutaminolysis bolsters chemotherapy while NRF2 promotes chemoresistance in KRAS-driven pancreatic cancers Undermining Glutaminolysis bolsters chemotherapy while NRF2 promotes chemoresistance in KRAS-driven pancreatic cancers Cancer Res. The gene discussed is KRAS; the disease is pancreatic neoplasm.